/TVRD
TVRD Stock - Tvardi Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$3.98+2.31%
+$0.09 (+2.31%) • Dec 19
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+486.2%upside
Target: $23.33
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TVRD
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.94 – $4.02
TARGET (TP)$23.33
STOP LOSS$3.66
RISK/REWARD1:60.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.11
52W High$43.65
52W Low$3.74
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $7.14M | $20.97M | $41.87M | $23.03M | $135.08M |
| Gross Profit | $6.33M | $14.54M | $34.35M | $21.47M | N/A |
| Gross Margin | 88.6% | 69.3% | 82.1% | 93.3% | 0.0% |
| Operating Income | $-55,781,000 | $-121,495,000 | $-87,535,000 | $-89,083,000 | $5.38M |
| Net Income | $-70,867,000 | $-118,513,000 | $-85,474,000 | $-88,441,000 | $8.41M |
| Net Margin | -993.0% | -565.2% | -204.2% | -384.1% | 6.2% |
| EPS | $-46.59 | $-1.85 | $-2.20 | $-62.77 | $6.39 |
Company Overview
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
50%
Hold / Neutral
3
50%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
3 Bullish3 Neutral/Bearish
Price Targets
$48
Average Target
↑ 1099.7% Upside
Now
$4
Low
$48
Average
$78
High
Based on 8 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 14th 2025 | Barclays | Downgrade | Equal Weight | $5 |
| October 14th 2025 | Raymond James | Downgrade | Market Perform | - |
| October 13th 2025 | Cantor Fitzgerald | Downgrade | Neutral | - |
| October 13th 2025 | Piper Sandler | Downgrade | Neutral | $4← $78 |
| October 13th 2025 | Barclays | Initiation | Overweight | $61 |
| July 14th 2025 | Raymond James | Initiation | Outperform | $62 |
| July 11th 2025 | Cantor Fitzgerald | Initiation | Overweight | $52 |
| June 12th 2025 | Piper Sandler | Initiation | Overweight | $78 |
| May 21st 2025 | Oppenheimer | Initiation | Outperform | $65 |
| May 15th 2025 | BTIG Research | Initiation | Buy | $55 |
Earnings History & Surprises
TVRDBeat Rate
33%
Last 3 quarters
Avg Surprise
-172.5%
EPS vs Estimate
Beats / Misses
1/2
Last 12 quarters
Latest EPS
$-0.59
Q4 2025
EPS Surprise History
Q2 25
-450.4%
$-3.22vs$-0.58
Q3 25
-96.1%
$-1.00vs$-0.51
Q4 25
+28.9%
$-0.59vs$-0.83
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 10, 2026 | $-0.55 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.83 | $-0.59 | +28.9% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-0.51 | $-1.00 | -96.1% | ✗ MISS |
Q2 2025 | May 13, 2025 | $-0.58 | $-3.22 | -450.4% | ✗ MISS |
Latest News
Tvardi Therapeutics Q3 EPS $(0.59) Beats $(0.92) Estimate
📈 PositiveBenzinga•Nov 13, 2025, 09:32 PM
Raymond James Downgrades Tvardi Therapeutics to Market Perform
📉 NegativeBenzinga•Oct 14, 2025, 02:11 PM
BTIG Maintains Buy on Tvardi Therapeutics, Lowers Price Target to $15
➖ NeutralBenzinga•Oct 13, 2025, 03:37 PM
Tivardi tanks on phase 2 data of TTI-101 in idiopathic pulmonary fibrosis
📉 NegativeSeeking Alpha•Oct 13, 2025, 02:42 PM
Barclays Initiates Coverage On Tvardi Therapeutics with Overweight Rating, Announces Price Target of $61
📈 PositiveBenzinga•Oct 13, 2025, 12:14 PM•Also:
Tvardi Therapeutics Said Preliminary Data From Phase 2 REVERT Trial of TTI-101 In Idiopathic Pulmonary Fibrosis Show That The Study Did Not Meet Its Goals
📉 NegativeBenzinga•Oct 13, 2025, 11:32 AM
Frequently Asked Questions about TVRD
What is TVRD's current stock price?
Tvardi Therapeutics, Inc. (TVRD) is currently trading at $3.98 per share. The stock has moved +2.31% today.
What is the analyst price target for TVRD?
The average analyst price target for TVRD is $23.33, based on 1 analyst.
What sector is Tvardi Therapeutics, Inc. in?
Tvardi Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is TVRD's market cap?
Tvardi Therapeutics, Inc. has a market capitalization of $0.04 billion, making it a small-cap company.
Does TVRD pay dividends?
No, Tvardi Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorATNM
Actinium Pharmaceuticals, Inc.
$1.69
Mkt Cap: $0.1B
CALC
CalciMedica, Inc.
$6.35
Mkt Cap: $0.1B
ELUT
Elutia Inc.
$0.59
Mkt Cap: $0.0B
FGEN
FibroGen, Inc.
$8.60
Mkt Cap: $0.0B
LTRN
Lantern Pharma Inc.
$3.26
Mkt Cap: $0.0B
LVTX
LAVA Therapeutics N.V.
$1.74
Mkt Cap: $0.0B
PDSB
PDS Biotechnology Corporation
$0.89
Mkt Cap: $0.0B
RVPH
Reviva Pharmaceuticals Holdings, Inc.
$0.60
Mkt Cap: $0.0B
TPST
Tempest Therapeutics, Inc.
$3.12
Mkt Cap: $0.0B
XLO
Xilio Therapeutics, Inc.
$0.67
Mkt Cap: $0.0B
Explore stocks similar to TVRD for comparison